Logo

DXCM

DexCom, Inc.

DXCM

DexCom, Inc. • NASDAQ
$63.45 ▲ 1.47% (+0.92)
Market Cap $24.82 B
52w High $93.25
52w Low $54.11
Dividend Yield 0%
P/E 35.25
Volume 2.25M
Outstanding Shares 391.19M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.209B ▲ $488.9M ▲ $283.8M ▲ 23.468% ▲ $0.73 ▲ $415.9M ▲
Q2-2025 $1.157B ▲ $476.2M ▲ $179.8M ▲ 15.539% ▲ $0.46 ▲ $308.8M ▲
Q1-2025 $1.036B ▼ $455.3M ▼ $105.4M ▼ 10.174% ▼ $0.27 ▼ $219M ▼
Q4-2024 $1.113B ▲ $466.9M ▲ $151.7M ▲ 13.624% ▲ $0.39 ▲ $274M ▲
Q3-2024 $994.2M $441.8M $134.6M 13.539% $0.35 $237.4M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $3.322B ▲ $7.5B ▲ $4.774B ▲ $2.726B ▲
Q2-2025 $2.929B ▲ $7.327B ▲ $4.754B ▲ $2.573B ▲
Q1-2025 $2.701B ▲ $6.752B ▲ $4.485B ▲ $2.267B ▲
Q4-2024 $2.579B ▲ $6.484B ▲ $4.382B ▲ $2.103B ▲
Q3-2024 $2.492B $6.354B $4.375B $1.979B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $283.8M ▲ $659.9M ▲ $192.8M ▲ $-175M ▼ $676.6M ▲ $579.4M ▲
Q2-2025 $179.8M ▲ $303M ▲ $-63.6M ▼ $-1.7M ▼ $254.2M ▼ $208.9M ▲
Q1-2025 $105.4M ▼ $183.8M ▼ $100.2M ▲ $12.5M ▲ $298.8M ▲ $96.8M ▼
Q4-2024 $151.7M ▲ $301.4M ▲ $-303.7M ▼ $-1.6M ▲ $-15.1M ▲ $176.8M ▲
Q3-2024 $134.6M $199.5M $210.3M $-736.5M $-316.8M $88.3M

Five-Year Company Overview

Income Statement

Income Statement Dexcom’s income statement shows a business that has moved from a high‑growth phase into more mature, but still strong, growth with improving profitability. Revenue has risen steadily each year, and profits have scaled along with it rather than lagging behind. Gross profit has grown faster than sales, which suggests better pricing power, manufacturing efficiency, or both. Operating profit has expanded meaningfully, indicating that the company is managing its overhead and sales costs well as it grows. Net income has become more consistent over time, with earlier volatility giving way to steadier earnings. Overall, the trend is of a company that is not just growing quickly, but also becoming more efficient and predictably profitable as it scales.

Balance Sheet

Balance Sheet The balance sheet reflects a growing medical technology company that is investing heavily but still keeping a reasonable financial foundation. Total assets have climbed each year, showing continued investment in technology, production capacity, and growth initiatives. Debt is meaningful and has increased over time, so leverage is something to watch, but it has not exploded relative to the size of the business. Equity has trended upward, supported by retained earnings, which points to value being built in the business rather than eroded. Cash balances are healthy but not excessive, suggesting the company prefers to put money to work rather than sit on it. Altogether, the balance sheet looks solid for a growth company, with some dependence on debt but no obvious signs of financial strain in the historical figures.

Cash Flow

Cash Flow Dexcom’s cash flow profile is a key strength. Cash generated from day‑to‑day operations has grown consistently, keeping pace with and even outstripping reported earnings, which is a good sign for quality of profits. Free cash flow has turned into a solid, recurring positive stream over the last several years, even after significant spending on equipment, manufacturing, and other long‑term investments. Capital spending has been sizable, reflecting the needs of a hardware‑plus‑software medical device business that must fund new production lines, sensors, and infrastructure. The fact that Dexcom can both reinvest meaningfully and still produce surplus cash suggests it has reached a more self‑funding, durable stage of its growth story.

Competitive Edge

Competitive Edge Dexcom holds a leading position in continuous glucose monitoring, supported by a combination of technology, brand, and ecosystem lock‑in. Its CGM systems are widely viewed as highly accurate and user‑friendly, which is crucial in a life‑critical category like diabetes care. The company benefits from strong brand recognition among both patients and clinicians, and its partnerships with insulin pump makers create deeply integrated systems that are hard for users to walk away from. Software tools for data analysis and remote monitoring add further stickiness and differentiate the offering beyond just the sensor hardware. The moat is reinforced by patents, regulatory approvals, and clinical trust, all of which take years for rivals to replicate. At the same time, the CGM space is competitive, with large players and potential pricing pressure, so sustaining this edge will require continued execution and innovation.

Innovation and R&D

Innovation and R&D Innovation is at the heart of Dexcom’s strategy and is a major contributor to its moat. The company has steadily rolled out improved generations of its CGM systems, shrinking device size, shortening warm‑up times, and simplifying usage. Its move into over‑the‑counter sensors for people with type 2 diabetes and broader metabolic tracking meaningfully expands its potential market beyond traditional insulin users. Looking ahead, longer‑wear sensors, the planned G8 platform with even smaller form factor and multi‑analyte capabilities, and AI‑driven features (like image‑based meal logging) signal an ambition to move from a single‑condition device maker toward a broader digital health and metabolic monitoring platform. This innovation agenda is promising but also increases execution risk, as the company must balance regulatory demands, user experience, and technical complexity while keeping reliability and safety paramount.

Summary

Dexcom appears to be a scaled, fast‑growing medical device company that has successfully transitioned from early‑stage growth to a more mature, cash‑generative phase while maintaining strong innovation momentum. Its income statement reflects consistent revenue expansion with improving profitability, while the balance sheet and cash flows show a business capable of funding its own growth and ongoing research. The company’s competitive position in continuous glucose monitoring is underpinned by technology, brand loyalty, ecosystem integration, and partnerships, but it operates in a competitive and highly regulated space where reimbursement, pricing, and rival technologies are ongoing risks. The robust pipeline—from improved CGM generations to broader metabolic and wellness applications—creates substantial opportunity but also depends on continued flawless execution and regulatory success. Overall, the historical data and qualitative factors depict a financially solid, innovation‑driven healthcare technology leader with both meaningful strengths and the usual risks that come with operating at the cutting edge of medical devices and digital health.

NEWS

November 30, 2025 · 12:35 AM UTC

DXCM DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM

Read more

November 29, 2025 · 10:27 PM UTC

DXCM DEADLINE ALERT: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DXCM

Read more

November 29, 2025 · 10:26 AM UTC

DXCM Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. (DXCM)

Read more

November 28, 2025 · 8:40 AM UTC

DexCom, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – DXCM

Read more

November 27, 2025 · 7:20 PM UTC

DXCM DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DXCM

Read more